HistoSonics raised $102M in a Series D funding round led by Alpha Wave Ventures to scale the launch of its non-invasive histotripsy platform.

Aug 15, 2024•over 1 year ago

Amount Raised

$102 Million

Round Type

series d

PlymouthHealthcare

Investors

State Of Wisconsin Investment BoardYonjin VentureLumira VenturesVenture InvestorsJohnson & Johnson Innovation Jjdc, Inc.Health Quest CapitalAmzak HealthAlpha Wave Ventures

Description

HistoSonics has completed an oversubscribed $102 million Series D financing to enhance its histotripsy platforms and support commercial growth. This funding will also initiate the company’s innovative BOOMBOX Master Study evaluating their Edison System for liver tumor treatment.

Company Information

Company

HistoSonics

Location

16305 36th Avenue North, 300

Plymouth, Minnesota, United States

About

HistoSonics is a growth phase company developing a non-invasive sonic beam therapy platform and procedure using the science of histotripsy. Histotripsy utilizes the pressure created by focused sound energy to liquefy and destroy targeted tissue, including diseased tissue and tumors, at sub-cellular levels. The company’s new platform delivers personalized, tissue specific treatments with precision and control, and without the undesirable side effects of many of today’s interventional and surgical modalities.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends